About Nautilus Biotechnology, Inc.
https://www.nautilus.bioNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
CEO
Sujal M. Patel
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
AH CAPITAL MANAGEMENT, L.L.C.
Shares:17.65M
Value:$33.9M
AH EQUITY PARTNERS BIO II, L.L.C.
Shares:16.3M
Value:$31.29M
PERCEPTIVE ADVISORS LLC
Shares:12.59M
Value:$24.18M
Summary
Showing Top 3 of 75
About Nautilus Biotechnology, Inc.
https://www.nautilus.bioNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $13.85M ▼ | $-13.57M ▲ | 0% | $-0.11 ▲ | $-11.96M ▲ |
| Q2-2025 | $0 | $15.46M ▼ | $-15.03M ▲ | 0% | $-0.12 ▲ | $-13.4M ▲ |
| Q1-2025 | $0 | $17.22M ▲ | $-16.61M ▲ | 0% | $-0.13 ▲ | $-14.99M ▼ |
| Q4-2024 | $0 | $13.63M ▼ | $-17.59M ▼ | 0% | $-0.14 ▼ | $-11.24M ▲ |
| Q3-2024 | $0 | $17.49M | $-16.45M | 0% | $-0.13 | $-14.83M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $131.43M ▼ | $200.91M ▼ | $31.78M ▼ | $169.14M ▼ |
| Q2-2025 | $147.87M ▲ | $213.19M ▼ | $32.09M ▼ | $181.09M ▼ |
| Q1-2025 | $138.81M ▲ | $227.69M ▼ | $33.26M ▼ | $194.44M ▼ |
| Q4-2024 | $129.89M ▼ | $242.74M ▼ | $34.01M ▼ | $208.73M ▼ |
| Q3-2024 | $140.61M | $259.7M | $36.27M | $223.43M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-13.57M ▲ | $-11.03M ▲ | $452K ▼ | $0 ▼ | $-10.58M ▼ | $-11.45M ▲ |
| Q2-2025 | $-15.03M ▲ | $-13.35M ▲ | $14.47M ▼ | $95K ▲ | $1.22M ▼ | $-13.75M ▲ |
| Q1-2025 | $-16.61M ▲ | $-13.94M ▲ | $19.51M ▼ | $18K ▼ | $5.59M ▼ | $-14.16M ▲ |
| Q4-2024 | $-17.59M ▼ | $-14.31M ▼ | $37.11M ▲ | $440K ▲ | $23.24M ▲ | $-14.56M ▼ |
| Q3-2024 | $-16.45M | $-13.11M | $-7.5M | $140K | $-20.48M | $-13.82M |
CEO
Sujal M. Patel
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
AH CAPITAL MANAGEMENT, L.L.C.
Shares:17.65M
Value:$33.9M
AH EQUITY PARTNERS BIO II, L.L.C.
Shares:16.3M
Value:$31.29M
PERCEPTIVE ADVISORS LLC
Shares:12.59M
Value:$24.18M
Summary
Showing Top 3 of 75